evaluated the efficacy and safety of T-DM1 in 49 advanced HER2-overexpressing NSCLC patients (29 IHC 2+ and 20 IHC 3+) who were previously treated. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.